ReviewCurrent medicinal chemistry2026
Current Attainments on Nanobiosensors for Diagnosing Atherosclerosis Biomarkers.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a chronic disease caused by inflammation in the blood vessel wall, which leads to plaque formation in the endothelial lining. Preexisting atherosclerosis contributes to various cardiovascular problems, including myocardial infarction, congestive cardiac failure, arrhythmias, and acute coronary syndrome, all of which are associated with higher postoperative mortality and morbidity. Rupturing of atherosclerosis poses a significant health concern as triggering a heart attack. Therefore, it is essential to identify atherosclerosis early to prevent health complications and their subsequent consequences. Atherosclerosis is typically diagnosed by angiograms, computerized tomography scans and stress tests. Additionally, various biomarkers are released by inflammatory cells in the surrounding tissue and artery walls during the pathogenesis of atherosclerosis. Quantifying these biomarkers can aid in diagnosing and determining the severity of atherosclerosis in relation to cardiovascular diseases. This review focuses on the recent advancements in understanding the formation of atherosclerosis and the implementation of biomarkers in nano biosensors.
Indexed as
Identifiers
40289981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.